Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 2

Conditions

Stomach Neoplasms 132Pancreatic Neoplasms 36Esophageal Neoplasms 19Biliary Tract Neoplasms 18Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 10Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Gastrointestinal Neoplasms 6Nasopharyngeal Carcinoma 5Colonic Neoplasms 5Adenocarcinoma 5Neoplasms 4Head and Neck Neoplasms 4Advanced Pancreatic Cancer 4Advanced Gastric Cancer 4Recurrence 3Rectal Neoplasms 3Gastric Adenocarcinoma 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2NSCLC 2Locally Advanced Pancreatic Cancer 2Gastric Cancer Peritoneal Metastases 2Gallbladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × S 1 (combination) × Clear all
NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT03013010 2025-12-08

PREACT

Shanghai Cancer Hospital, China

Phase 3 Completed
204 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT02564367 2021-04-29

S-1 adjuvant

AIO-Studien-gGmbH

Phase 1/2 Completed
30 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01552980 2012-03-28

mSOX

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡